Most stroke survivors and their families recognise the pattern even if nobody’s named it directly – progress happens, sometimes quickly at first, then slows, plateaus, and stops. What remains gets classified as permanent. Here’s what’s actually driving that ceiling:

• Dead neurons don’t regenerate: When blood supply to a brain region is cut off, those neurons die. The brain compensates partially through plasticity – but it can’t replace what was lost. Rehabilitation works with what’s left. That’s a hard constraint on how far it can go.
• Neuroinflammation keeps running after the acute phase: The post-stroke inflammatory response is necessary initially – but in many patients it doesn’t fully resolve. Chronic neuroinflammation surrounding the infarct actively interferes with the plasticity rehabilitation is trying to harness. The therapy is working against an environment pushing back.
• Damaged neural pathways can’t be rebuilt through exercise: A stroke severs connections between neurons, not just the neurons themselves. Alternative routes can be trained, but they’re slower, less efficient, and more cognitively demanding than the originals – and those costs accumulate.
• The recovery window closes and nothing in conventional medicine reopens it: The first three to six months post-stroke is when plasticity peaks. After that, progress slows dramatically. Patients carrying significant deficits at one or two years are typically told further recovery is unlikely. Stem cell therapy is being explored specifically because it may reopen that window biologically rather than accepting it as closed.

Rehabilitation is valuable and necessary – but it has a ceiling that leaves many patients with considerably less function than before their stroke. For a broader look at how regenerative medicine is being applied to neurological damage, brain damage stem cell therapy covers the clinical approach in detail.